ADC Therapeutics
ADCT
38 hedge funds and large institutions have $56.4M invested in ADC Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 11 closing their positions.
59% more capital invested
Capital invested by funds: $35.4M → $56.4M (+$21M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 41 → 38 (-3)
10.78% less ownership
Funds ownership: 48.93% → 38.15% (-11%)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$1.06M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$987K |
| 3 |
Goldman Sachs
New York
|
+$375K |
| 4 |
Morgan Stanley
New York
|
+$109K |
| 5 |
Jane Street
New York
|
+$93.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$2.96M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$1.48M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$964K |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$958K |
| 5 |
BlackRock
New York
|
-$475K |
ADCT Hedge Fund Activity: Q4 2023 in Review
38 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2023, worth a combined $56.4M — up 59% from $35.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADCT and 8 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Redmile Group, adding an estimated $1.06M. The largest seller was Sio Capital Management, exiting entirely with an estimated $2.96M sold.
- 38 institutional investors held ADC Therapeutics (ADCT) as of Q4 2023, down from 41 in Q3 2023.
- Funds reported $56.4M of ADC Therapeutics stock for Q4 2023, up 59% quarter-over-quarter.
- 8 funds opened new ADC Therapeutics positions in Q4 2023 and 11 closed out, a net change of -3 holders.
- The largest ADC Therapeutics buyer in Q4 2023 was Redmile Group, an estimated $1.06M added.
- The largest ADC Therapeutics seller in Q4 2023 was Sio Capital Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q4 2023.